ClinicalTrials.gg
CompletedNCT02023164Updated Feb 9, 2024Results posted

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

A Phase 3 interventional study of JDP-205 Injection and Diphenhydramine in Acute Urticaria, sponsored by JDP Therapeutics, Inc.. Completed at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-09.

Sponsored by JDP Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Urticaria with a site in Canada — 1 open to participants now, 2 under way, 1 of them phase 3. Urticaria · Canada.

Enrollment
10th of 13
36 · median 182
Started
2013
with 1 other
Phase 3
4 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
JDP Therapeutics, Inc.

Among the 13 studies in Urticaria with a site in Canada, this one is the 10th largest by enrollment, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 2nd registered.

Urticaria

148 studies on the registry are indexed under Urticaria; 20 are open to participants now.

Browse Urticaria studies →

Open to participants now

1 of the 13 studies in Urticaria with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 12 Urticaria studies recruiting now, 3 (25%) set no upper age limit and 6 (50%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Urticaria with a site in Canada, or all of them as a file.
02

Study summary

This is a multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics.

Read the detailed description

Multicenter, parallel group, randomized, double-blind pilot Phase III clinical study of JDP-205 (cetirizine) injection, versus diphenhydramine injection, 50 mg/mL (Benadryl or generic equivalent), in approximately 36 patients with acute urticaria requiring treatment in Hospital Emergency Departments, Urgent Care Centers and Allergy Clinics. This study will be conducted in 33 patient who either present themselves to the hospital emergency department, allergy clinic or urgent care centers with acute urticaria or developed acute urticaria following a allergen challenge at an allergy clinic.

Following informed consent, eligibility will be established, capturing baseline data including vitals, age, medical history, and medications taken prior to coming to the clinical study site. Following data collection, study subjects will be randomized in a 1:1 ratio to receive study drug of either cetirizine 10 mg IV or diphenhydramine, 50 mg IV. Baseline data including vital signs, the extent of urticaria and erythema, the severity of pruritus, and the level of sedation will be recorded prior to and at 1 hour and 2 hours post study drug administration, and at the time of "Readiness for Discharge". The actual time at which the investigator determines that the subject is ready for discharge (physically and mentally fit) from the study site will also be recorded. At these same time intervals, subjects will be asked to self-rate (recorded by study staff) severity of their pruritus and level of sedation (recorded by study staff).

Twenty-four hours following discharge from the study site, study staff will call the subject to ask them a few short questions to follow-up on the treatment of their acute urticaria. All adverse and serious adverse events experienced by the subjects following informed consent, and all data captured will be recorded in the source documents and/or case report forms.

03

Conditions studied

  • Acute Urticaria

Keywords

  • urticaria
  • allergic reaction
  • cetirizine
  • JDP-205
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patients are eligible to be included in the study only if they meet all of the following criteria:

Inclusion criteria

Inclusion Criteria:

  • Male or female patients with a diagnosis of acute urticaria associated with an acute allergic reaction to a known (e.g. food, medication, insect bites) or unknown allergen who need treatment with an injectable antihistamine to alleviate their symptoms;
  • 18 years of age or older;
  • Be willing and able to give ;
  • Patients with a Physician Pruritus Severity Score ≥ 1 (determined by the investigator);
  • Patients with an Extent of Urticaria/Erythema Score ≥ 1 (determined by the investigator).

Exclusion criteria

Exclusion Criteria:

  • Receipt of an drug or device, within the past 30 days;
  • Patients in whom an antihistamine may be (e.g. narrow angle glaucoma, symptomatic prostatic hypertrophy);
  • Patients who, in the opinion of the investigator, may not tolerate an IV injection of diphenhydramine 50 mg, or cetirizine 10 mg;
  • Receipt of any antihistamine (H1 antagonist) within the past 4 hours regardless of the route of administration, e.g. diphenhydramine, cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine;
  • Receipt of an H2 antagonist within the past 12 hours;
  • Receipt of doxepin within the past 48 hours; doxepin is an antidepressant, but it also has antihistamine properties;
  • Receipt of by the oral, IV, IM, or inhalational routes route within the past 48 hours to manage an acute allergic reaction;
  • Receipt of epinephrine (EpiPen or any other brand) within the past 1 hour;
  • Has known allergy to hydroxyzine, cetirizine or levocetirizine, or diphenhydramine;
  • Pregnancy or breastfeeding;
  • Patients who require epinephrine immediately to manage their acute allergic symptoms;
  • Patients who have an acute reaction to medication they are taking (e.g. antibiotics, ACE inhibitors, NSAIDs) and who cannot stop the medication;
  • Patients who, based on their medical history or in the opinion of the investigator, have chronic idiopathic urticaria, hereditary angioedema, urticaria to antihistamines, or dermatological disease that interferes with evaluation of a therapeutic response;
  • Urticaria not associated with an acute allergic reaction;
  • Any condition that in the view of the investigator makes the subject unsuitable for enrollment in this study;
  • History of or other known immunodeficiency;
  • Major medical or psychiatric illness, other than acute urticaria, at the time of presentation;
  • Inability to provide .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Test Drug

    JDP-205 Injection, 10 mg/mL, 1 mL

    Drug: JDP-205 Injection

  • Active comparator
    Control

    Diphenhydramine Injection, 50 mg/mL, 1 mL

    Drug: Diphenhydramine

Interventions

  • Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes

    Also known as: Cetirizine, Quzyttir

  • Diphenhydramine Injection, 50 mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes

    Also known as: Benadryl, DPH

06

What researchers measure

Primary outcomes

  1. Extent of Urticaria/Erythema Score (Physician Assessment)

    Extent of Urticaria/Erythema Score (Physician Assessment), capturing extent of urticaria/erythema, using the Body Chart (adopted from Burn Chart). Extent of Urticaria/Erythema Score is the average of the 2 scores: 1. Percentage of body area using the body chart (adopted from burn Chart) 0 = none, 1= mild (,25% body coverage), 2 = moderate (25-50% body coverage, 3 = Severe/intense .50% body coverage 2. Intensity of redness (adopted from PASI) 0 = none, 1 = mile (light pink) 2= moderate (pink), 3 =severe/intense (red)

    Time frame: Baseline, 1 hour, 2 hour, Discharge (up to 4 hours)

  2. Physician Pruritus Severity Score

    Physician Pruritus Severity Score based on patient expression of severity of itchiness. 0= none 1 = Mild (patient expresses itchiness but tolerable, and does not scratch 2= moderate definite awareness, bothersome, intermittently scratch affected area 3= severe difficult to tolerate scratch vigorously

    Time frame: Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first

  3. Patient Pruritis Severity Score

    Patient Pruritis Severity Score based on severity of itching at time of assessment. How severly are your hives itching at the moment? 0 = none 1= mild minimal awareness easily tolerated 2 = moderate definite awareness quite bothersome 3= severe difficult to tolerate

    Time frame: Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first

  4. Composite Acute Urticaria Score Change From Baseline

    A composite acute urticaria score, the sum of Extent of urticaria/erythema score (Physician), Physician pruritis score and Patient pruritis severity score. A composite acute urticaria score which the sum of the above three parameters (i.e. 0-9) was calculated post hoc for each patient at each time point and then their score change from the baseline were compared between the two treatment groups. Higher values indicate a worse outcome.

    Time frame: Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)

Secondary outcomes

  1. Sedation Scores and Time to Readiness for Discharge

    Time from study drug injection to time to readiness for discharge based on composite sedation score at readiness for discharge consist of Physician Sedation Score and Patient Sedation Score Physician Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Patient is completely alert. Does not look tired at all), 1 = Mild (Patient sitting/lying comfortably, and looks tired), 2 = Moderate (Drowsy, with occasional eyes closing), 3 = Severe (Asleep, with eyes closed but responds to minor motor stimulation), 4 = Extremely Severe (Asleep; does not respond to minor motor stimulation) Patient Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Not drowsy at all), 1 = Mild (Slightly drowsy), 2 = Moderate (Quite drowsy), 3 = Severe (Extremely drowsy), 4 = Extremely Severe (Asleep, cannot self-rate) Higher the sedation score = worse outcome A composite sedation score which is the sum of the two parameters.

    Time frame: Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.

  2. Percentage of Patients Requiring Additional Medication

    Percentage of Patients Requiring Additional Medication (Rescue Medication)

    Time frame: Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)

  3. Sedation Scores and Time to Readiness for Discharge HH:MM

    Time from study drug injection to time to readiness for discharge based on Physician and Patient Sedation Scores Physician Sedation Score: 0 = None 1 = Mild 2 = Moderate 3= Severe 4 = Extremely Severe Patient Sedation Score 0= None 1- Mild 2 = Moderate 3= Severe 4 = Extremely Severe Higher scores = worse outcome

    Time frame: Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.

07

Results

Posted Feb 9, 2024
Limitations and caveats
This was a pilot Phase 3 study, therefore a description of the statistical analyses was not documented in a separate Statistical Analysis Plan, and instead, are described within the content of the protocol and within the CSR. The adverse event data were collected in a non-systematic fashion, consisting of adverse events documented as observed by the study site staff and captured based on verbal communication (phone call) to the patient during the follow-up period.

Participant flow

Recruitment of patients who either present to Hospital Emergency Departments, allergy clinics or Urgent Care Centers with acute urticaria, or develop acute urticaria following allergen challenge at an Allergy Clinic.

Treatment Period
Participant flow — Treatment Period
MilestoneTest DrugControl
Started1617
Completed1617
Not completed00
24-Hour Follow-Up
Participant flow — 24-Hour Follow-Up
MilestoneTest DrugControl
Started1617
Completed1615
Not completed02
Withdrew: Lost to follow-up02

Outcome measures

PrimaryExtent of Urticaria/Erythema Score (Physician Assessment)

Extent of Urticaria/Erythema Score (Physician Assessment), capturing extent of urticaria/erythema, using the Body Chart (adopted from Burn Chart). Extent of Urticaria/Erythema Score is the average of the 2 scores: 1. Percentage of body area using the body chart (adopted from burn Chart) 0 = none, 1= mild (,25% body coverage), 2 = moderate (25-50% body coverage, 3 = Severe/intense .50% body coverage 2. Intensity of redness (adopted from PASI) 0 = none, 1 = mile (light pink) 2= moderate (pink), 3 =severe/intense (red)

Time frame:
Baseline, 1 hour, 2 hour, Discharge (up to 4 hours)
Reported as:
Mean · units on a scale
Extent of Urticaria/Erythema Score (Physician Assessment)
units on a scaleTest DrugControl
Baseline1.91 ± 0.611.74 ± 0.89
1 Hour1.53 ± 0.741.12 ± 1.05
2 Hour0.89 ± 0.601.35 ± 1.03
Discharge1.09 ± 0.550.97 ± 0.94
PrimaryPhysician Pruritus Severity Score

Physician Pruritus Severity Score based on patient expression of severity of itchiness. 0= none 1 = Mild (patient expresses itchiness but tolerable, and does not scratch 2= moderate definite awareness, bothersome, intermittently scratch affected area 3= severe difficult to tolerate scratch vigorously

Time frame:
Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first
Reported as:
Median · score on a scale
Physician Pruritus Severity Score
score on a scaleTest DrugControl
Baseline Assessment2. (1. to 3.00)2.00 (0.00 to 3.00)
1 hour Assessment1.0 (0.0 to 2.0)1. (0.0 to 2.)
2 hour Assessment1.0 (0.0 to 2.0)1.0 (0.0 to 2.0)
Discharge Assessment1.0 (0.0 to 2.0)0.0 (0.0 to 2.0)
PrimaryPatient Pruritis Severity Score

Patient Pruritis Severity Score based on severity of itching at time of assessment. How severly are your hives itching at the moment? 0 = none 1= mild minimal awareness easily tolerated 2 = moderate definite awareness quite bothersome 3= severe difficult to tolerate

Time frame:
Baseline, 1 hour, 2 hour, discharge or up to 4 hours post intervention, whichever came first
Reported as:
Mean · score on a scale
Patient Pruritis Severity Score
score on a scaleTest DrugControl
Baseline2.19 ± 0.662.24 ± 1.03
1 Hour0.56 ± 0.630.82 ± 1.01
2 Hour0.56 ± 0.530.90 ± 1.29
Discharge0.50 ± 0.520.59 ± 1.06
PrimaryComposite Acute Urticaria Score Change From Baseline

A composite acute urticaria score, the sum of Extent of urticaria/erythema score (Physician), Physician pruritis score and Patient pruritis severity score. A composite acute urticaria score which the sum of the above three parameters (i.e. 0-9) was calculated post hoc for each patient at each time point and then their score change from the baseline were compared between the two treatment groups. Higher values indicate a worse outcome.

Time frame:
Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)
Reported as:
Mean · score on a scale
Composite Acute Urticaria Score Change From Baseline
score on a scaleTest DrugControl
1-Hour Assessment-3.13 ± 1.41-3.26 ± 2.10
2-Hour Assessment-4.28 ± 1.12-3.65 ± 2.21
Discharge Assessment-3.81 ± 1.12-3.82 ± 2.28
SecondarySedation Scores and Time to Readiness for Discharge

Time from study drug injection to time to readiness for discharge based on composite sedation score at readiness for discharge consist of Physician Sedation Score and Patient Sedation Score Physician Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Patient is completely alert. Does not look tired at all), 1 = Mild (Patient sitting/lying comfortably, and looks tired), 2 = Moderate (Drowsy, with occasional eyes closing), 3 = Severe (Asleep, with eyes closed but responds to minor motor stimulation), 4 = Extremely Severe (Asleep; does not respond to minor motor stimulation) Patient Sedation Score Score ranged from 0 to 4 (0=min, 4=max) 0 = None (Not drowsy at all), 1 = Mild (Slightly drowsy), 2 = Moderate (Quite drowsy), 3 = Severe (Extremely drowsy), 4 = Extremely Severe (Asleep, cannot self-rate) Higher the sedation score = worse outcome A composite sedation score which is the sum of the two parameters.

Time frame:
Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.
Reported as:
Mean · score on a scale
Sedation Scores and Time to Readiness for Discharge
score on a scaleTest DrugControl
Physician sedation score at Readiness for Discharge0.19 ± 0.400.35 ± 0.49
Patient sedation score at Readiness for Discharge0.25 ± 0.450.71 ± 0.69
Composite sedation score at Readiness for Discharge0.44 ± 0.811.06 ± 0.97
SecondaryPercentage of Patients Requiring Additional Medication

Percentage of Patients Requiring Additional Medication (Rescue Medication)

Time frame:
Baseline, 1 hour, 2 hour, Discharge (an average of 1 day)
Reported as:
Count of participants · Participants
Percentage of Patients Requiring Additional Medication
ParticipantsTest DrugControl
Rescue Required at Discharge ]Reported by HCP12
Additional Rescue Required 24 Hours After Discharged as Reported by Patient1013
SecondarySedation Scores and Time to Readiness for Discharge HH:MM

Time from study drug injection to time to readiness for discharge based on Physician and Patient Sedation Scores Physician Sedation Score: 0 = None 1 = Mild 2 = Moderate 3= Severe 4 = Extremely Severe Patient Sedation Score 0= None 1- Mild 2 = Moderate 3= Severe 4 = Extremely Severe Higher scores = worse outcome

Time frame:
Assessed at discharge or up to 4 hours post intervention, whichever came first data at discharge reported.
Reported as:
Mean · Hours
Sedation Scores and Time to Readiness for Discharge HH:MM
HoursTest DrugControl
Sedation Scores and Time to Readiness for Discharge HH:MM1.65 ± 0.532.23 ± 1.20

Adverse events

Collected over Adverse events were collected from time of informed consent through the 24-hour follow-up *after discharge (an average of 36 hours). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Drug0/16 (0%)0/16 (0%)14/16 (87.5%)
Control0/17 (0%)0/17 (0%)12/17 (70.6%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTest DrugControl
RashSkin and subcutaneous tissue disorders4/162/17
Rash pruriticSkin and subcutaneous tissue disorders3/163/17
PruritisSkin and subcutaneous tissue disorders3/161/17
UrticariaSkin and subcutaneous tissue disorders2/162/17
DizzinessNervous system disorders1/161/17
SomnolenceNervous system disorders1/161/17
Burning sensationGeneral disorders1/161/17
HeadacheNervous system disorders1/160/17
Abdominal discomfortGastrointestinal disorders1/160/17
Lip swellingGastrointestinal disorders1/160/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test DrugControlTotal
<=18 years000
Between 18 and 65 years151732
>=65 years101
Age, Continuous
Age, Continuous(Years)Test DrugControlTotal
Mean36 ± 1739 ± 1437 ± 15
Sex: Female, Male
Sex: Female, Male(Participants)Test DrugControlTotal
Female6915
Male10818
Region of Enrollment
Region of Enrollment(participants)Test DrugControlTotal
Canada91019
United States7714
08

Study locations

6 sites
  • University of Cincinnati, Department of Emergency Medicine
    Cincinnati, Ohio 45267-0769, United States
  • OSU Hospitals, Department of Emergency Medicine
    Columbus, Ohio 43210, United States
  • Glengarry Memorial Hospital, Independent Practice
    Alexandria, Ontario, Canada
  • Ottawa Hospital, Civic Campus
    Ottawa, Ontario, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Del Carpio Independent Practice
    Montréal, Quebec H3G 1L5, Canada
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2024, 9 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 30, 2013
Start
Jul 2013
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Feb 9, 2024
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02023164
Lead sponsor
JDP Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 30, 2013
Start date
Jul 2013
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Feb 9, 2024
Last update
Feb 9, 2024

Study contacts

Janine North, B.S.
study director · TerSera Therapeutics LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion